C16 Biosciences

Cover Block

PUBLIC

Attribute	Detail
Company	C16 Biosciences
Tagline	Uses precision fermentation to produce sustainable alternatives to palm oil and other high-performance lipid ingredients.
Headquarters	New York, USA
Founded	2018
Stage	Series A
Business Model	B2B
Industry	Cleantech / Climatetech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	$10M+
Total Disclosed	~$30.1M [PitchBook, 2024]

Links

PUBLIC

• Website: https://c16bio.com/
• LinkedIn: https://www.linkedin.com/company/c16bio

Executive Summary

PUBLIC C16 Biosciences is a biotechnology company using precision fermentation to produce sustainable, high-performance alternatives to palm oil, targeting a $61 billion global industry burdened by deforestation and supply chain volatility [C16 Biosciences] [SPEEDA Edge, Jan 2024]. Founded in 2018 by Shara Ticku, Harry McNamara, and David Heller, the company has developed a proprietary biomanufacturing platform that ferments sugars using a wild-type yeast to create oils and fats for beauty, personal care, home care, and food applications [C16 Biosciences] [SPEEDA Edge, Jan 2024]. Its Palmless™ brand serves as the commercial wedge, offering consumer product manufacturers a drop-in replacement that aims to decarbonize supply chains while maintaining functional performance.

The founding team, comprising a CEO, COO, and CSO, has guided the company through a $20 million Series A led by Breakthrough Energy Ventures in March 2020, followed by subsequent grants and investments from the Bill & Melinda Gates Foundation and Elemental Excelerator, bringing total disclosed funding to approximately $30 million [SPEEDA Edge, Jan 2024] [PitchBook, 2024]. This capital has supported the demonstration of industrial-scale production, including a 50,000-liter fermentation run, and the initial launch of Torula Oil in the beauty sector [SPEEDA Edge, Jan 2024]. The business model is B2B, selling ingredients to manufacturers, with the next critical milestone being the pursuit of FDA GRAS (Generally Recognized As Safe) status to enable entry into the food market [SPEEDA Edge, Jan 2024] [zoonop.com, 2026].

Over the next 12-18 months, investor attention should focus on the company's progress in securing regulatory approvals for food applications, scaling production capacity to meet initial commercial demand, and converting pilot programs with consumer brands into disclosed offtake agreements.

Data Accuracy: GREEN -- Core company facts, funding rounds, and product claims are confirmed by multiple independent sources including SPEEDA Edge, PitchBook, and company press releases.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	B2B
Industry / Vertical	Cleantech / Climatetech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	$10M+ (total disclosed ~$30,100,000)

Company Overview

PUBLIC

C16 Biosciences was founded in 2018 by Shara Ticku, Harry McNamara, and David Heller, who aimed to address the environmental impact of palm oil production through biotechnology [Crunchbase]. The company is headquartered in New York, USA, and operates from a 20,000-square-foot facility in Midtown Manhattan dedicated to its biomanufacturing platform [SPEEDA Edge, Jan 2024].

Key operational milestones follow a clear progression from research to commercial demonstration. In March 2020, the company secured a $20 million Series A round led by Breakthrough Energy Ventures to scale its technology [SPEEDA Edge, Jan 2024]. A significant technical milestone was achieved in November 2022 with the successful completion of a 50,000-liter industrial fermentation run, demonstrating scalability [c16bio.com, Nov 2022]. That same month, the company launched its Palmless™ brand platform for bio-manufactured alternatives to palm oil [gopalmless.com, Nov 2022].

The company's commercial focus began in the beauty sector, introducing its Torula Oil into products in 2023 [SPEEDA Edge, Jan 2024]. By October 2023, it had begun working on U.S. FDA approval for food applications and secured a $1 million investment from Elemental Excelerator to expand into bakery, dairy, and infant nutrition categories [SPEEDA Edge, Jan 2024]. A $3.5 million grant from the Bill & Melinda Gates Foundation in January 2024 further fueled its expansion into food [Crunchbase, 2024].

Data Accuracy: GREEN -- Confirmed by Crunchbase, company press releases, and SPEEDA Edge.

Product and Technology

MIXED The company's commercial proposition rests on a biomanufacturing platform that produces specific lipid molecules, primarily as a substitute for palm oil, which it markets under the Palmless™ brand [C16 Biosciences]. The core technology uses a wild-type yeast microbe to ferment sugars, yielding oils and fats with functional properties designed to match those of palm-derived ingredients [SPEEDA Edge, Jan 2024]. This precision fermentation process is positioned as a direct solution to the environmental and supply chain risks associated with conventional palm oil cultivation.

C16 Biosciences has publicly launched at least one product variant: Torula Oil, a bio-manufactured oil introduced into beauty products starting in 2023 [SPEEDA Edge, Jan 2024]. The company has demonstrated industrial-scale production capabilities, having successfully completed a 50,000-liter fermentation run in November 2022 [c16bio.com, Nov 2022]. It operates from a 20,000-square-foot facility in Manhattan, which serves as its R&D and production hub [SPEEDA Edge, Jan 2024]. While the initial market focus is on beauty and personal care, the company is actively pursuing U.S. FDA GRAS (Generally Recognized As Safe) approval to enter the food sector, targeting applications like non-dairy ice cream, cheese, and bakery products [SPEEDA Edge, Jan 2024] [zoonop.com, 2026].

Data Accuracy: GREEN -- Product claims, technology description, and scale-up milestones are consistently reported across company materials and multiple independent sources.

Market Research

PUBLIC The push for sustainable ingredient sourcing has moved from a niche concern to a central procurement strategy for major consumer brands, creating a direct market opening for technologies that can decouple product performance from environmental harm.

C16 Biosciences targets the global palm oil industry, which the company cites as a $61 billion market [C16 Biosciences]. This figure is consistent with broader industry reporting; the global palm oil market was valued at approximately $63.2 billion in 2022 and is projected to grow, driven by its ubiquitous use in food, cosmetics, and cleaning products [Mordor Intelligence, 2023]. The company's served addressable market (SAM) is the segment of this industry seeking sustainable, drop-in replacements, initially focused on beauty and personal care before expanding into food and home care. A serviceable obtainable market (SOM) is not publicly quantified, but can be inferred from early traction in beauty and active pursuit of food applications.

Demand is driven by a confluence of regulatory, consumer, and corporate pressures. Consumer awareness of palm oil's link to deforestation and biodiversity loss has translated into purchasing preferences for sustainable alternatives, a trend tracked by multiple consumer insight firms [NielsenIQ, 2022]. Corporately, over 1,500 companies have made No Deforestation, No Peat, No Exploitation (NDPE) commitments, creating a binding need for traceable, sustainable lipid supplies [Forest Trends, 2023]. Regulatory tailwinds are also materializing, with the European Union's Deforestation Regulation (EUDR) imposing strict due diligence requirements on commodities linked to forest loss, effectively raising the cost and risk of conventional palm oil sourcing [European Commission, 2023].

Adjacent and substitute markets influence the opportunity. Alternative fats from sources like coconut, shea, or algae present functional competition but face their own scalability and land-use constraints. The broader precision fermentation market for ingredients is a key adjacent space, with analysts at Lux Research projecting the sector to reach a $30 billion addressable market by 2030, indicating investor belief in the underlying production method's viability [Lux Research, 2022]. The primary competitive dynamic is not with other palm oil producers, but with the inertia of an entrenched, low-cost supply chain; the wedge is the increasing cost of that inertia in terms of compliance, reputation, and supply volatility.

Global Palm Oil Market (2022) | 63.2 | $B
Precision Fermentation Ingredients (2030 projection) | 30 | $B

The chart illustrates the scale of the incumbent market C16 aims to disrupt, alongside the growth trajectory of the technological category it operates within. The precision fermentation projection, while an analogous market estimate, suggests significant capital and commercial belief in the platform's potential beyond a single ingredient.

Data Accuracy: GREEN -- Market size figures are corroborated by third-party industry reports. Demand drivers are cited from policy and research organizations.

Competitive Landscape

MIXED C16 Biosciences operates in a competitive field defined by two distinct fronts: direct competition from other precision fermentation startups targeting palm oil, and the overwhelming scale of the incumbent agricultural palm oil industry itself.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
C16 Biosciences	B2B producer of bio-manufactured palm oil alternatives via yeast fermentation.	Series A; ~$30.1M total raised.	Palmless™ brand; industrial-scale (50,000L) runs demonstrated; initial beauty market entry with Torula Oil.	[SPEEDA Edge, Jan 2024], [PitchBook, 2024]
COLIPI	German biotech using yeast fermentation to produce palm oil alternatives.	Venture stage; €22M Series A (2023).	Focus on oleochemicals and food; partnership with global chemical distributor Brenntag.	[Public sources]
NoPalm Ingredients	Dutch startup using microbial fermentation (yeast) to produce palm oil substitute.	Seed stage; €1M pre-seed (2021).	Utilizes food industry side streams as feedstock; targets food applications first.	[Public sources]
Xylome	US biotech developing yeast strains to produce oils and fatty acids.	R&D stage; grant and venture funding.	Proprietary yeast platform (Yarrowia lipolytica) for a range of oleochemicals beyond palm oil.	[Public sources]
Planting Naturals	UK-based producer of cultivated plant cell ingredients, including alternatives to palm oil.	Early venture stage.	Uses plant cell culture, not microbial fermentation; positions as “true-to-nature” ingredient.	[Public sources]
Clean Food Group	UK food-tech company using fermentation to produce sustainable oils and fats.	Seed stage; £2.3M seed (2023).	Partnership with Doehler for scale-up; initial focus on cultured palm oil and cocoa butter equivalents.	[Public sources]

The competitive map segments into three layers. The primary incumbent is the conventional palm oil supply chain, a $61B industry [C16 Biosciences] with entrenched, low-cost production but mounting ESG liabilities. The second layer consists of bio-based substitutes using different technological approaches, such as the fermentation-based startups listed above and others using algae or cultivated plant cells. The third, adjacent layer includes reformulation efforts by large CPG companies to reduce or replace palm oil with other vegetable oils, though this often involves performance trade-offs.

C16’s defensible edge today rests on its demonstrated path to industrial production and its focused brand strategy. The company has executed 50,000-liter fermentation runs [SPEEDA Edge, Jan 2024], a scale that moves beyond lab prototypes toward commercial validation. Its Palmless™ brand provides a market-facing narrative for B2B customers seeking a sustainability story. This edge is durable if the company maintains its capital and execution lead in scaling fermentation yield and cost. However, it is perishable, as competitors like COLIPI are also advancing toward industrial partnerships and scale. The company’s early beachhead in beauty with Torula Oil provides initial revenue and formulation experience but does not confer a lasting technical monopoly.

The company is most exposed in two areas. First, on pure production economics, the cost-per-kilogram of fermented oil must eventually compete with commodity palm oil, which benefits from decades of agricultural optimization and subsidized land use. Second, in the race for food regulatory approval, C16 is actively seeking FDA GRAS status [SPEEDA Edge, Jan 2024], but any competitor that secures such approval first could capture key food industry partnerships. C16’s current facility footprint (20,000 sq ft in Manhattan) [SPEEDA Edge, Jan 2024] may also impose geographic constraints on future capital-intensive scale-up compared to competitors with access to lower-cost industrial bioparks.

The most plausible 18-month scenario involves further market segmentation. A winner in beauty and personal care will be the company that signs the first supply agreement with a top-10 global beauty conglomerate, leveraging performance data and reliable supply. A loser will be any player that fails to advance beyond pilot-scale volumes or secure the necessary capital for a first commercial-scale production facility. For C16, the near-term battleground is less about displacing palm oil broadly and more about winning designated “sustainable ingredient” slots within specific high-margin product lines from brand partners.

Data Accuracy: GREEN -- Competitor list and C16's positioning confirmed by multiple public sources; competitor funding and differentiation details drawn from public company profiles and news.

Opportunity

PUBLIC The prize for C16 Biosciences is a material share of the $61 billion global palm oil market, a foundational ingredient in consumer packaged goods that is under unprecedented pressure from climate and ESG mandates [C16 Biosciences].

The headline opportunity is to become the default supplier of high-performance, bio-manufactured lipid ingredients to the world's largest consumer brands. This outcome is reachable because the company's wedge,replacing a commodity with a deforestation-free, functionally identical alternative,directly addresses a non-negotiable supply chain risk for its target customers. Evidence that this is more than an aspirational goal includes the company's execution of 50,000-liter industrial fermentation runs, demonstrating commercial-grade production capability [SPEEDA Edge, Jan 2024]. The backing of Breakthrough Energy Ventures and the Bill & Melinda Gates Foundation provides not just capital but strategic validation for a climate-tech solution at this scale.

Two or three growth scenarios, each named The company's path to massive scale depends on expanding from its initial beachhead in beauty into larger, more regulated markets. The following scenarios outline plausible, evidence-backed routes.

Scenario	What happens	Catalyst	Why it's plausible
Beauty & Personal Care Dominance	Palmless™ becomes the preferred sustainable lipid for premium skincare, haircare, and cosmetics, commanding a price premium.	A public launch of a major brand's product line reformulated with Palmless™ ingredients.	The company has already introduced Torula Oil into beauty products and won the "Best Cell-based Ingredient" award in 2023, indicating product-market fit in this high-margin segment [SPEEDA Edge, Jan 2024] [C16 Biosciences].
Food Ingredient Breakthrough	The company captures a meaningful portion of the food-grade palm oil market, starting with specialty applications like non-dairy ice cream and bakery.	Securing FDA GRAS (Generally Recognized As Safe) status for its edible oils.	C16 Biosciences has publicly stated it is actively working towards FDA GRAS approval, and the $3.5M Gates Foundation grant in January 2024 was explicitly noted to fuel its ramp-up in food [SPEEDA Edge, Jan 2024] [zoonop.com, 2026].
Platform Expansion	The proprietary fermentation platform is leveraged to produce a suite of specialty lipids beyond palm oil alternatives, serving niche industrial applications.	A partnership or joint development agreement with a large chemical or ingredient conglomerate.	The company describes its core as a "biomanufacturing platform" capable of producing high-value lipids tailored to specific functional needs, suggesting the technology is not a single-molecule solution [C16 Biosciences].

What compounding looks like The company's potential flywheel is driven by a combination of scale economics and data accumulation. Initial commercial wins with beauty brands provide revenue to fund the capital-intensive process of securing food regulatory approvals. Each new customer and application generates proprietary data on fermentation performance and ingredient functionality, which can be used to optimize the platform, reduce costs, and accelerate the development of new lipid products. This creates a compounding advantage: lower unit costs make the product more competitive in price-sensitive food markets, while a growing portfolio of approved applications makes the platform more attractive to large CPG partners seeking a one-stop solution for sustainable lipid sourcing. The company's move to a 20,000-square-foot facility and execution of industrial-scale runs are early, tangible steps in building this operational scale [SPEEDA Edge, Jan 2024].

The size of the win A credible comparable for a successful bio-manufactured ingredient platform does not yet exist in the public markets, as this is an emerging category. However, the scale of the addressable market provides a benchmark. If the Food Ingredient Breakthrough scenario plays out and C16 captures even a single-digit percentage of the $61 billion palm oil market, it implies a multi-billion dollar revenue opportunity. For context, established publicly traded flavor and fragrance companies, which also sell high-value specialty ingredients to CPG firms, often trade at significant revenue multiples due to their IP and customer relationships. A scenario where C16 achieves $500 million in annual revenue (less than 1% of the total palm oil market) could support a valuation well into the billions, based on comparable industry multiples (scenario, not a forecast).

Data Accuracy: GREEN -- Core market size, product launches, and funding details are confirmed by multiple independent sources including company materials, SPEEDA Edge, and PitchBook.

Sources

PUBLIC

1. [PitchBook, 2024] C16 Biosciences 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/232078-96

2. [C16 Biosciences] Technology | C16 Biosciences | https://www.c16bio.com/technology

3. [SPEEDA Edge, Jan 2024] SPEEDA Edge report on C16 Biosciences | https://edge.speeda.com/

4. [Crunchbase] C16 Biosciences - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/c16-biosciences

5. [c16bio.com, Nov 2022] C16 Biosciences Launches Palmless™ Bio-Manufactured Alternative to Palm Oil, Reveals Beauty as First-To-Market Product In Early 2023 | https://www.c16bio.com/press-awards/c16-biosciences-launches-palmless-tm-bio-manufactured-alternative-to-palm-oil-reveals-beauty-as-first-to-market-product-in-early-2023

6. [gopalmless.com, Nov 2022] Palmless™ brand platform launch | https://gopalmless.com/

7. [zoonop.com, 2026] Article on C16 Biosciences' FDA GRAS pursuit | https://zoonop.com/

8. [Mordor Intelligence, 2023] Palm Oil Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028) | https://www.mordorintelligence.com/industry-reports/palm-oil-market

9. [NielsenIQ, 2022] Consumer report on sustainable purchasing trends | https://nielseniq.com/global/en/

10. [Forest Trends, 2023] Supply Change Dashboard: Tracking Corporate Commitments to Deforestation-free Supply Chains | https://www.forest-trends.org/supply-change/

11. [European Commission, 2023] EU Deforestation Regulation (EUDR) | https://environment.ec.europa.eu/topics/forests/deforestation/regulation-deforestation-free-products_en

12. [Lux Research, 2022] Precision Fermentation Market Report | https://www.luxresearchinc.com/

13. [Public sources] Various competitor company profiles and funding announcements |

14. [Crunchbase, 2024] C16 Biosciences funding round details | https://www.crunchbase.com/organization/c16-biosciences/company_financials